Publication | Open Access

Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)

First-line PembrolizumabMedicineImmunologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung Cancer